(+)-JQ1

目录号:S7110

(+)-JQ1 Chemical Structure

Molecular Weight(MW): 456.99

(+)-JQ1是一种BET bromodomain抑制剂,作用于BRD4(1/2),无细胞试验中IC50为77 nM/33 nM,结合到BET家族的所有溴结构域,而不结合到BET家族以外的溴结构域。

规格 价格 库存 购买数量  
RMB 2227.39 现货
RMB 4667.45 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck该产品发表文献23篇:

产品安全说明书

Epigenetic Reader Domain抑制剂选择性比较

生物活性

产品描述 (+)-JQ1是一种BET bromodomain抑制剂,作用于BRD4(1/2),无细胞试验中IC50为77 nM/33 nM,结合到BET家族的所有溴结构域,而不结合到BET家族以外的溴结构域。
特性 (+)-JQ1比(-)-JQ1更有效。
靶点
BRD4 (2) [1]
(Cell-free assay)
BRD4 (1) [1]
(Cell-free assay)
33 nM 77 nM
体外研究

(+)-JQ1对映体直接结合到BET bromodomain结构域的Kac结合位点。(+)-JQ1(500 nM)与染色质竞争性结合到BRD4,导致NMC细胞分化和生长停滞。通过Ki67染色减少,证明了(+)-JQ1(500 nM)减弱NMC 797和Per403细胞系的快速增殖。(+)-JQ1(500 nM)作用于NMC 797细胞,有效降低BRD4靶基因的表达。(+)-JQ1作用于NMC 11060细胞,抑制细胞活力, IC50为4 nM。[1](+)-JQ1作用于MM细胞系,强抑制MYC表达。(+)-JQ1抑制KMS-34和LR5增殖,IC50分别为 68 nM和98 nM。(+)-JQ1(500 nM)处理MM.1S细胞,导致S期细胞比例明显下降,随之细胞停滞在G0/G1期增多。(+)-JQ1(500 nM)通过β-半乳糖苷酶染色,导致明显的细胞衰老。(+)-JQ1(800 nM)处理CD138+病患衍生的MM样本,显著降低细胞活力。[2] (+)-JQ1抑制LP-1细胞生长,GI50 为98 nM。(+)-JQ1(625 nM)导致LP-1细胞在G0/G1期的百分数增高。(+)-JQ1(500 nM)作用于LP-1细胞,抑制MYC, BRD4 和CDK9表达。[3](+)-JQ1(1 μM)处理潜伏感染的Jurkat T细胞,激活HIV转录。(+)-JQ1(50 μM)作用于Jurkat和HeLa细胞,主要刺激Tat依赖性的HIV转录。(+)-JQ1(5 μM)作用于J-Lat A2细胞,诱导Brd4解离,从而使Tat招募SEC到HIV启动子上,诱导Pol II CTD磷酸化和病毒转录。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
K1  NHu4VYpE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NVzv[lg6OjVyL{WwNE8yODByIH7N Ml\ZNlQwPDhxN{KgbC=> NYXRXYlxTE2VTx?= NU\lSVV3cW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDDkc5NmNSCjbnSgeIlu\S1iZHXw[Y5l\W62IH3hco5meg>? NXHobFk3OjZ5MEe4PFE>
BCPAP MX;D[YxtKF[rYXLpcIl1gSCDc4PhfS=> MnryNlUxNzVyMD:xNFAxKG6P NWXsUHFpOjRxNEivO|IhcA>? M{TEV2ROW09? NH3tS4FqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz MX:yOlcxPzh6MR?=
K1  M1PsVmNmdGxiQ4njcIUhSXO|YYm= NUD3enVtOjVyL{WwNE8yODByIH7N M2DKZlczKGh? Ml\ZSG1UVw>? M{nheYFzemW|dIOgZ4VtdCCleXPs[UBifCCJMD;HNUBxcGG|ZR?= NInnfG4zPjdyN{i4NS=>
BCPAP NX7EbJRWS2WubDDDfYNt\SCDc4PhfS=> NF\BZZgzPTBxNUCwM|ExODBibl2= M2PRfFczKGh? MX7EUXNQ NH\5VIRienKnc4TzJINmdGxiY4njcIUh[XRiR{CvS|EheGijc3W= NFjuOXMzPjdyN{i4NS=>
Hep3B NISyXYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\TZ4wxNTFyIN88US=> MoDvOUBl NIr5UGlFVVOR M2nE[WlEPTB;MD6wPEDPxE1? NUjYZXBrOjZ3N{WxOlc>
HCCLM3 NWDqUG9zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3j3dlAuOTBizszN MVW1JIQ> NXX2W3p3TE2VTx?= M3HSOGlEPTB;MD6xOEDPxE1? MoK2NlY2PzVzNke=
HuH7 MnPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXabHVzOC1zMDFOwG0> M{LRUFUh\A>? MmfaSG1UVw>? M{LYVWlEPTB;MD6yNUDPxE1? MVKyOlU4PTF4Nx?=
HepG2 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYKwMVExKM7:TR?= MoXROUBl MkPaSG1UVw>? MULJR|UxRTBwM{Sg{txO M4fUd|I3PTd3MU[3
SMMC7721 NIHsZpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIroc4oxNTFyIN88US=> MYW1JIQ> M3:2N2ROW09? NX7GN2RSUUN3ME2wMlQyKM7:TR?= MkH4NlY2PzVzNke=
BEL7402 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1:3U|AuOTBizszN MWG1JIQ> M{\jXWROW09? NV\XdlYzUUN3ME2wMlQ4KM7:TR?= M3fQSFI3PTd3MU[3
MHCC97H NVrZN4RRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjvWJAxNTFyIN88US=> NIPWO5Q2KGR? M1\lemROW09? MWnJR|UxRTBwNEGg{txO MUCyOlU4PTF4Nx?=
Hep3B MYPD[YxtKEO7Y3zlJGF{e2G7 NXzoVpg6OC5zL{CuOU8zNjVizszN NILqUW01QCCq MWXEUXNQ MXLs[YFleyC2bzDhJJN2[nO2YX70bYFtKGGlY4XteYxifGmxbjDv[kBJS0NiY3XscJMhcW5ic4XiMWcyKHCqYYPlxsA> MmDoNlY2PzVzNke=
HCCLM3 M3;uc2NmdGxiQ4njcIUhSXO|YYm= NEDBTHExNjFxMD61M|IvPSEQvF2= MVe0PEBp NV;mfHBVTE2VTx?= MX;s[YFleyC2bzDhJJN2[nO2YX70bYFtKGGlY4XteYxifGmxbjDv[kBJS0NiY3XscJMhcW5ic4XiMWcyKHCqYYPlxsA> M2LLSVI3PTd3MU[3
Hep3B NV3lVGdkSXCxcITvd4l{KEG|c3H5 MWOwMlEwOC53L{KuOUDPxE1? MV[0PEBp M1rEO2ROW09? M1rjcoFkfGm4YYTld{Bk[XOyYYPlMVMh[W6mIHPhd5Bie2VvOTDlfJBz\XO|aX;uJIFv\CCrbnT1Z4VlKFCDUmCgZ4xm[X[jZ3WgZZMhf2WubDDhd{BkgXSxY3jyc41mKGNicnXs[YF{\SCrboTvJJRp\SCleYTvdIxie21iZoLvcUBucXSxY3jvcoRzcWF? Ml7kNlY2PzVzNke=
HCCLM3 NITkdnRCeG:ydH;zbZMhSXO|YYm= NYjnV3JHOC5zL{CuOU8zNjVizszN MVe0PEBp NGDRdHdFVVOR Mon6ZYN1cX[jdHXzJINie3Cjc3WtN{BidmRiY3HzdIF{\S17IHX4dJJme3Orb36gZY5lKGmwZIXj[YQhWEGUUDDjcIVifmGpZTDhd{B4\WyuIHHzJIN6fG:laILvcYUh[yC{ZXzlZZNmKGmwdH:geIhmKGO7dH;wcIF{dSCocn;tJI1qfG:laH;u[JJq[Q>? NH:2blYzPjV5NUG2Oy=>
A549 M1LlO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUKwMlEuOTBizszN M37HRVczKGh? MVXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M17ET|I3PDF3MkK1
H157 NHHKRnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHPNE4yNTFyIN88US=> MYW3NkBp MXfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NGX3TZgzPjRzNUKyOS=>
H1299 M2rUV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLZTZVjOC5zLUGwJO69VQ>? NX:wSVE1PzJiaB?= MnzZbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NF\IbFQzPjRzNUKyOS=>
A549 NULZNI9GTnWwY4Tpc44hSXO|YYm= MXGxM|IvPS93IN88US=> M{jLdVEzKGh? NX61VIVGyqC5ZXHrcJkh\GWlcnXhd4VlKEKlbD2yJIxmfmWucx?= NF7EPYEzPjRzNUKyOS=>
H1299 MmjoSpVv[3Srb36gRZN{[Xl? NEDybHoyNzJwNT:1JO69VQ>? MWOxNkBp NXvCbYZxyqC5ZXHrcJkh\GWlcnXhd4VlKEKlbD2yJIxmfmWucx?= MUGyOlQyPTJ{NR?=
H157 M3jhV2Z2dmO2aX;uJGF{e2G7 NXHEWIxGOS9{LkWvOUDPxE1? NHzYbmoyOiCq M1XaRoRm[3KnYYPl[EBFWjRiZYjwdoV{e2mxbh?= MXKyOlQyPTJ{NR?=
H1299 MoPNSpVv[3Srb36gRZN{[Xl? MVWxM|IvPS93IN88US=> MmrnNVIhcA>? NFntbWtl\WO{ZXHz[YQhTFJ2IHX4dJJme3Orb36= M1TzXFI3PDF3MkK1
C8161 MWTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MV2wMVIh|ryP MnnWOEBl Mn3ISG1UVw>? M2X6NoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= Mk\pNlY{QTd{MkO=
Mel285 NWi1V|M{S2WubDDWbYFjcWyrdImgRZN{[Xl? MkPUNE0zKM7:TR?= NHvMPY01KGR? NHrCXWpFVVOR MVzk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? Ml;yNlY{QTd{MkO=
Mel290 NE\tcWhE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M2nCZlAuOiEQvF2= Mn7YOEBl NXzjdFI1TE2VTx?= MWnk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M2DleVI3Ozl5MkKz
92.1 M3HybWNmdGxiVnnhZoltcXS7IFHzd4F6 NYCyOmxuOC1{IN88US=> MUm0JIQ> NEXtW|VFVVOR MYLk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M{TabVI3Ozl5MkKz
Omm1.3 NX\4bpJyS2WubDDWbYFjcWyrdImgRZN{[Xl? Mk\TNE0zKM7:TR?= NFn3S3o1KGR? NV3HR21PTE2VTx?= MYLk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NWHLW3kyOjZ|OUeyNlM>
Mel202 M{CwUWNmdGxiVnnhZoltcXS7IFHzd4F6 MXewMVIh|ryP MknmOEBl M2PhcGROW09? MYLk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NYnXU2dbOjZ|OUeyNlM>
Mel270 NXO4O5JDS2WubDDWbYFjcWyrdImgRZN{[Xl? NXPGeJo{OC1{IN88US=> NV;a[ZR2PCCm NEHqfYpFVVOR MXzk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NVTWbVBWOjZ|OUeyNlM>
Omm1 NFi4VZlE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M2PhZlAuOiEQvF2= M{XaRlQh\A>? NYj0RZdSTE2VTx?= M4npNYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M3v3blI3Ozl5MkKz
92.1 MnXzRZBweHSxc3nzJGF{e2G7 NYnMbY5xPTByIH7N MUm0PEBp MofXSG1UVw>? NGTrSWdqdmS3Y3XzJIFxd3C2b4Ppdy=> M{LUcFI3Ozl5MkKz
Omm1.3 NWH4PYYxSXCxcITvd4l{KEG|c3H5 MVO1NFAhdk1? NXjJWHJWPDhiaB?= MWHEUXNQ M4n2Oolv\HWlZYOgZZBweHSxc3nz MWOyOlM6PzJ{Mx?=
92.1 MoTYR4VtdCCFeXPs[UBCe3OjeR?= M1u2UlUxOCCwTR?= M{j2eFI1NzR6L{eyJIg> M4TGSGROW09? NHvUOndqdmS3Y3XzJJRp\SClZXzsJIFk[3WvdXzheIlwdiCjdDDzeYIuTzIEoB?= M3HId|I3Ozl5MkKz
Omm1.3 M1zpSWNmdGxiQ4njcIUhSXO|YYm= MkDkOVAxKG6P M2jLN|I1NzR6L{eyJIg> MVLEUXNQ MX;pcoR2[2W|IITo[UBk\WyuIHHjZ5VufWyjdHnvckBifCC|dXKtS|HDqA>? MmDtNlY{QTd{MkO=
A549 NFnKOnZHfW6ldHnvckBCe3OjeR?= MkLyNVAxNzRyMD:xNFAxKG6P NVLicnN{OjRiaB?= NW\6dJljfXC{ZXf1cIF1\XNiYX7kJIFkfGm4YYTld{BUUVKWMR?= MYWyOlIyOjF7OR?=
MCF-7 MV3GeY5kfGmxbjDBd5NigQ>? MUKxNFAwPDByL{GwNFAhdk1? MmD4NlQhcA>? MlrweZBz\We3bHH0[ZMh[W6mIHHjeIl3[XSnczDTTXJVOQ>? NYWyfohbOjZ{MUKxPVk>
HEK293 MoTMSpVv[3Srb36gRZN{[Xl? NGLlXJYyODBxNECwM|ExODBibl2= MWOyOEBp MmDPeZBz\We3bHH0[ZMh[W6mIHHjeIl3[XSnczDTTXJVOQ>? MUeyOlIyOjF7OR?=
858 NV7KR3lPS2WubDDWbYFjcWyrdImgRZN{[Xl? NVfGN2ZHOC1zIN88US=> NVT4Z45rPSCm NY\1VHp3TE2VTx?= NEOwNJNl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MnrTNlYzODZ|M{O=
DDR2L63V M3H3R2NmdGxiVnnhZoltcXS7IFHzd4F6 M1PIblAuOSEQvF2= MkHGOUBl MnfpSG1UVw>? MnjG[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M4fXdlI3OjB4M{Oz
BE(2)-C MlHrR4VtdCCYaXHibYxqfHliQYPzZZk> NWLGZ5llOSEQvF2= NILYdFIyNTRiZB?= NFPZSHZl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>? MYiyOlA3PzR4NB?=
IMR-32 M3zDbWNmdGxiVnnhZoltcXS7IFHzd4F6 M1[xWlEh|ryP MWqxMVQh\A>? MX3k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlic3nncolncWOjboTsfS=> Mn;CNlYxPjd2NkS=
JF MUjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NWnGd|dsOSEQvF2= NGK2epYyNTRiZB?= M{G2cIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6 MX6yOlA3PzR4NB?=
BE(2)-M17 M4PifWNmdGxiVnnhZoltcXS7IFHzd4F6 M{\CfFEh|ryP MV6xMVQh\A>? M{DMcIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6 MoTGNlYxPjd2NkS=
SK-N-SH NXfpdnpGS2WubDDWbYFjcWyrdImgRZN{[Xl? M2\lbFEh|ryP M{fYVFEuPCCm NXXBXJUx\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJNq\26rZnnjZY51dHl? MoHDNlYxPjd2NkS=
SK-N-DZ  NFPST5NE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MV[xJO69VQ>? NGPKd2QyNTRiZB?= M1z5O4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6 NFvVTYkzPjB4N{S2OC=>
HMC-1.1  NVXIZZd[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nTN|UuPTByMDDuUS=> M1uzZ|Q5KGh? M4T1U2ROW09? M2jzcolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MnHWNlYxPTV|MEO=
HMC-1.2 MkXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVu1MVUxODBibl2= Mnm4OFghcA>? M1;6U2ROW09? NVHBdo1bcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NUnxW|VHOjZyNUWzNFM>
ROSA KIT WT  M3n1fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PR[FUuPTByMDDuUS=> NYDoXmpGPDhiaB?= NGG1VmlFVVOR M3OyZ4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MYeyOlA2PTNyMx?=
ROSA KIT D816V M{DkSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVm1MVUxODBibl2= M4fyWlQ5KGh? M2PofmROW09? M{mwSolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NYr1eHVbOjZyNUWzNFM>
HMC-1.1  M3vKeGFxd3C2b4Ppd{BCe3OjeR?= NIrhVFYzODBvNUCwNEBvVQ>? Mk\pOFghcA>? NH20VnBFVVOR NX7pb3FzcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NUe5[|E{OjZyNUWzNFM>
HMC-1.2 NXqyTndsSXCxcITvd4l{KEG|c3H5 M{fuWVIxOC13MECwJI5O NHLxW5U1QCCq MVnEUXNQ NXfjS5V[cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NXrP[Yx3OjZyNUWzNFM>
ROSA KIT WT  MXLBdI9xfG:|aYOgRZN{[Xl? MmPaNlAxNTVyMECgcm0> M2nSbFQ5KGh? M3;xc2ROW09? M1rFSolv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MmLtNlYxPTV|MEO=
ROSA KIT D816V MlnhRZBweHSxc3nzJGF{e2G7 NYHTemF7OjByLUWwNFAhdk1? NELBXIw1QCCq MVnEUXNQ M2Li[Ilv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MUiyOlA2PTNyMx?=
494H MmOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLEO|IhcA>? NH3n[ZlFVVOR MXnJR|UxRTBwMUKyxtExNjByNDFOwG0> M4G4RVI2QTR2NU[2
493H NYLjRmhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPqO|IhcA>? M4LmcmROW09? MmDRTWM2OD1yLkC0O:KyOC5yMEmg{txO MlWzNlU6PDR3Nk[=
716H MmHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGriPW44OiCq NVfNPGJTTE2VTx?= NXW2NopyUUN3ME2wMlIyOsLzMD6wN|Qh|ryP NX3w[XRjOjV7NES1OlY>
148I NVfOW3Q4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYi3NkBp MXfEUXNQ NFrHcGFKSzVyPUCuNlg1yrFyLkCzOUDPxE1? M4HwTlI2QTR2NU[2
98Sc MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPDO|IhcA>? M3zmO2ROW09? MX3JR|UxRTBwMUG1xtExNjByNDFOwG0> NUm0WVlTOjV7NES1OlY>
89R NUK2XG1rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXe3NkBp MnriSG1UVw>? MWjJR|UxRTBwMUK2xtExNjByMzFOwG0> NWTZSVk4OjV7NES1OlY>
494L MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVe3NkBp NHToeFBFVVOR M1z1dmlEPTB;MD6zNVfDuTBwMEGyJO69VQ>? MoT3NlU6PDR3Nk[=
493L MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{GyNFczKGh? MXHEUXNQ MVXJR|UxRTBwMEWwxtExNjBzMTFOwG0> MnLtNlU6PDR3Nk[=
148L MkD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUC1XYRvPzJiaB?= M1jzNWROW09? NInJfIVKSzVyPUCuNVQ3yrFyLkCxO{DPxE1? MV[yOVk1PDV4Nh?=
98L NHLSUIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfMVGo4OiCq Mn;jSG1UVw>? M{\qZWlEPTB;MD6zNFnDuTBwMEK5JO69VQ>? NV;POnVpOjV7NES1OlY>
OS17 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmKxO|IhcA>? NYe5cYZYTE2VTx?= NYjGS5VYUUN3ME2wMlA4QcLzMD6wNFMh|ryP NGfPTWozPTl2NEW2Oi=>
OS9 M4eyUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYG3NkBp MmniSG1UVw>? M3jib2lEPTB;MD60NFbDuTBwMEK4JO69VQ>? NUTFTYdtOjV7NES1OlY>
MG63 M1vPU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX:3NkBp NICxPZNFVVOR NX65[Fl7UUN3ME2wMlEyPMLzMD6wNlUh|ryP MUeyOVk1PDV4Nh?=
SAOS2 Ml22S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37LblczKGh? NYTHZ|dOTE2VTx?= NGro[IxKSzVyPUCuNlE4yrFyLkCwN{DPxE1? M1TFNVI2QTR2NU[2
U2OS NIW0ToZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTvToFPPzJiaB?= NVvJcVhYTE2VTx?= M1;QSGlEPTB;MD6xPVjDuTBwMEC4JO69VQ>? MWSyOVk1PDV4Nh?=
SJSA-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELCR2w4OiCq NEDke3lFVVOR NXHxfYxIUUN3ME2wMlExOMLzMD6wNVAh|ryP MVmyOVk1PDV4Nh?=
494H NVyzcGF4SXCxcITvd4l{KEG|c3H5 MlXONE4zPS9yLkWvNU4xKM7:TR?= M{PWclI1KGh? NHLkOmVFVVOR MVHpcoNz\WG|ZYOgcIV3\Wy|IH;mJINt\WG4ZXSgZ4F{eGG|ZT2zxsA> NWf3Z|dvOjV7NES1OlY>
148I MnfTRZBweHSxc3nzJGF{e2G7 NEnwOFAxNjJ3L{CuOU8yNjBizszN NW\jepZ3OjRiaB?= NH[0RolFVVOR M4f1Xolv[3KnYYPld{Bt\X[nbIOgc4Yh[2ynYY\l[EBk[XOyYYPlMVPDqA>? NGfMTVQzPTl2NEW2Oi=>
OS17 MoG1RZBweHSxc3nzJGF{e2G7 NYHXPWk2OC5{NT:wMlUwOS5yIN88US=> NVjjPYVoOjRiaB?= NWfK[mNWTE2VTx?= NUntTFdKcW6lcnXhd4V{KGyndnXsd{Bw\iClbHXheoVlKGOjc4Dhd4UuO8Li M2nkTVI2QTR2NU[2
494H MXnBdI9xfG:|aYOgRZN{[Xl? M1G3PFHjiIoQvF2= NWH1VnRnPDhiaB?= Mo\RSG1UVw>? MorobY5lfWOnczDj[YxtKGGyb4D0c5NqeyC|aXfubYZq[2GwdHz5 MlLENlU6PDR3Nk[=
148I NUHtSY1zSXCxcITvd4l{KEG|c3H5 MX[x5qCK|ryP NXO4PW8xPDhiaB?= MlW2SG1UVw>? MkPibY5lfWOnczDj[YxtKGGyb4D0c5NqeyC|aXfubYZq[2GwdHz5 M2\DZVI2QTR2NU[2
OS17 Mmf4RZBweHSxc3nzJGF{e2G7 NXXjfpk{OeLCid88US=> Mo\5OFghcA>? NXG3[JpWTE2VTx?= M2TnOYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3nncolncWOjboTsfS=> NG\lVVMzPTl2NEW2Oi=>
MOLM13 NVP0S4JqSXCxcITvd4l{KEG|c3H5 NUfPTVVsOjVyIH7N MlLYOFghcA>? M4XEW2ROW09? MUfpcoR2[2W|IIPp[45q\mmlYX70cJkh[XCxcITvd4l{KGOxdILlZZRu\W62IIfpeIgheXWrenHyeIlvcWJ? NVjsUnFkOjVyNUO4NlU>
MV4-11  NEHiTHZCeG:ydH;zbZMhSXO|YYm= MVeyOVAhdk1? NXL0XIE4PDhiaB?= MV\EUXNQ NIm4[GlqdmS3Y3XzJJNq\26rZnnjZY51dHliYYDvdJRwe2m|IHPveJJm[XSvZX70JJdqfGhicYXpfoFzfGmwaXK= MU[yOVA2Ozh{NR?=
MOLM13 NES3dVhHfW6ldHnvckBCe3OjeR?= NHfBTWUzPTBibl2= MYKyOEBp MmDGSG1UVw>? NWLvZlh7\W6qYX7j[ZMheXWrenHyeIlvcWJvaX7keYNm\CCvb4LlJJAzOSxiQlnNMEBidmRiY3zlZZZm\CCSQWLQ M2rCd|I2ODV|OEK1
MV4-11  MVnGeY5kfGmxbjDBd5NigQ>? MUGyOVAhdk1? NFKwRYozPCCq NWXhTXJtTE2VTx?= NV;6XmJ[\W6qYX7j[ZMheXWrenHyeIlvcWJvaX7keYNm\CCvb4LlJJAzOSxiQlnNMEBidmRiY3zlZZZm\CCSQWLQ NEH4TGozPTB3M{iyOS=>
MOLM13 MULBdI9xfG:|aYOgRZN{[Xl? NVHldoRxOjVyIH7N NEG4fFU1QCCq NXPScZdPTE2VTx?= MnfTbY5lfWOnczDzbYdvcW[rY3HueIx6KGGyb4D0c5NqeyClb4Ty[YF1dWWwdDD3bZRpKHCxbnH0bY5q[g>? M33MV|I2ODV|OEK1
MV4-11  NXr4O4t6SXCxcITvd4l{KEG|c3H5 MUiyOVAhdk1? NWLveXg1PDhiaB?= MmflSG1UVw>? MkXobY5lfWOnczDzbYdvcW[rY3HueIx6KGGyb4D0c5NqeyClb4Ty[YF1dWWwdDD3bZRpKHCxbnH0bY5q[g>? NVrOeVVOOjVyNUO4NlU>
Hela NV7VTpZlS2WubDDWbYFjcWyrdImgRZN{[Xl? MmezNE02ODBibl2= NHjmeVI4OiCq MXPEUXNQ M2npbIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MWCyOVAxQTJ7NR?=
HBL-1 NWnEWnIyS2WubDDWbYFjcWyrdImgRZN{[Xl? Ml;iNE02ODBibl2= M1HVclczKGh? MmLsSG1UVw>? Mlmx[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NFnzb44zPTByOUK5OS=>
HLY-1 NYPsdJF4S2WubDDWbYFjcWyrdImgRZN{[Xl? NVSzWZd1OC13MECgcm0> MkfuO|IhcA>? Mkj1SG1UVw>? MVfk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NF3rPYczPTByOUK5OS=>
OCI-Ly3 MYjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NEf5TZgxNTVyMDDuUS=> NWC5VFd5PzJiaB?= M2D4emROW09? NYXGfFVu\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NWXNPIxxOjVyMEmyPVU>
OCI-Ly10 M1HFTWNmdGxiVnnhZoltcXS7IFHzd4F6 MkjwNE02ODBibl2= Ml7HO|IhcA>? NF;rSpZFVVOR NX;0V3Jj\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M1vaRlI2ODB7Mkm1
SU-DHL-4 NUjofZF4S2WubDDWbYFjcWyrdImgRZN{[Xl? NX\xd49{OC13MECgcm0> NFj3foc4OiCq MXrEUXNQ NGe3VVhl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NVOwWYI5OjVyMEmyPVU>
SU-DHL-5 NV3tb4hPS2WubDDWbYFjcWyrdImgRZN{[Xl? MmHUNE02ODBibl2= M1LHeFczKGh? NVvKWJFDTE2VTx?= NUnGWYRb\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NY\BUZRiOjVyMEmyPVU>
SU-DHL-6 NXTtRZFrS2WubDDWbYFjcWyrdImgRZN{[Xl? MkDCNE02ODBibl2= MXO3NkBp MYDEUXNQ MkGz[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NUHRb3R1OjVyMEmyPVU>
SU-DHL-10 NG\Vd2VE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M{jPRlAuPTByIH7N NVjoRnlbPzJiaB?= MkmzSG1UVw>? NH;YS4Zl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M3zxUFI2ODB7Mkm1
RC-K8 MUTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MYqwMVUxOCCwTR?= Mn7LO|IhcA>? NFniNXdFVVOR Mkfu[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MXWyOVAxQTJ7NR?=
OCI-Ly8 NEDMTGRE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MWOwMVUxOCCwTR?= MnTOO|IhcA>? NVyzWXFmTE2VTx?= NWj2U2Vn\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MVOyOVAxQTJ7NR?=
OCL-Ly18 Mnr6R4VtdCCYaXHibYxqfHliQYPzZZk> MmP0NE02ODBibl2= MmXYO|IhcA>? MYTEUXNQ NHvscYZl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MlLxNlUxODl{OUW=
OCI-Ly3 NVzo[GUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3G2b|E4Oi9{NUCvOVAxKG6P NHfBepczNzdiZB?= M3jQdGROW09? MUXpcoR2[2W|IHPlcIwu[3mlbHWgZZJz\XO2IHH0JJN2[i2JMTD3bZRpKG2rbnntZYwh[2WubDDk[YF1cMLi NGjvNZczPTByOUK5OS=>
OCI-Ly8 NFe4TlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXpPI1QOTd{L{K1NE82ODBibl2= MWqyM|ch\A>? M3HJXWROW09? M3nwdolv\HWlZYOgZ4VtdC2leXPs[UBienKnc4SgZZQhe3WkLVexJJdqfGhibXnubY1idCClZXzsJIRm[XSqwrC= MY[yOVAxQTJ7NR?=
SU-DHL-4 NXzJZXU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXSxO|IwOjVyL{WwNEBvVQ>? MYKyM|ch\A>? NVfsbWl6TE2VTx?= M1fUbIlv\HWlZYOgZ4VtdC2leXPs[UBienKnc4SgZZQhe3WkLVexJJdqfGhibXnubY1idCClZXzsJIRm[XSqwrC= M{HPZ|I2ODB7Mkm1
SU-DHL-10 NEjJbFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVWxO|IwOjVyL{WwNEBvVQ>? NHv2e|czNzdiZB?= NIrT[5BFVVOR NU[yXG9ZcW6mdXPld{Bk\WyuLXP5Z4xmKGG{cnXzeEBifCC|dXKtS|Ehf2m2aDDtbY5qdWGuIHPlcIwh\GWjdHlCpC=> MU[yOVAxQTJ7NR?=
OCI-Ly3 NHGxbJFCeG:ydH;zbZMhSXO|YYm= M3XON|E4Oi9{NUCgcm0> MlfOO4Q> MVfEUXNQ M{DkeYlv[3KnYYPld{Bk[XOyYYPlMVMwPyCjY4Tpeol1gcLic3nncolncWOjboTsfS=> NH22Z28zPTByOUK5OS=>
OCI-Ly8 MkT5RZBweHSxc3nzJGF{e2G7 M4DDTFE4Oi9{NUCgcm0> MoH1O4Q> NEXRN4xFVVOR MWLpcoNz\WG|ZYOgZ4F{eGG|ZT2zM|ch[WO2aY\peJnDqHOrZ37p[olk[W62bIm= NYPLXFhqOjVyMEmyPVU>
SU-DHL-4 MmHqRZBweHSxc3nzJGF{e2G7 M2n3SFE4Oi9{NUCgcm0> M33CWVdl MUHEUXNQ MoTubY5kemWjc3XzJINie3Cjc3WtN{84KGGldHn2bZR6yqC|aXfubYZq[2GwdHz5 NX;EbZZvOjVyMEmyPVU>
SU-DHL-10 M3rsS2Fxd3C2b4Ppd{BCe3OjeR?= MWexO|IwOjVyIH7N MYK3[C=> MXfEUXNQ M3HSfYlv[3KnYYPld{Bk[XOyYYPlMVMwPyCjY4Tpeol1gcLic3nncolncWOjboTsfS=> MV6yOVAxQTJ7NR?=

... Click to View More Cell Line Experimental Data

体内研究 (+)-JQ1(50 mg/kg)处理携带NMC 797移植瘤的小鼠,抑制肿瘤生长。(+)-JQ1(50 mg/kg) 抹消掉携带NMC 797移植瘤的小鼠的NUT核斑点, 与竞争性结合到核染色质相一致。(+)-JQ1(50 mg/kg)处理NMC 797移植瘤, 显著诱导(31级)角蛋白表达。(+)-JQ1(50 mg/kg)处理携带NMC移植瘤的小鼠模型,促进分化,肿瘤衰退,延长寿命。[1](+)-JQ1(50 mg/kg)处理静脉注射MM.1S-luc+细胞,携带原位移植瘤的SCID米色小鼠,与对照组动物相比,显著延长小鼠的总生存期。[2](+)-JQ1(50 mg/kg,腹腔注射)处理携带Raji移植瘤的小鼠,显著提高小鼠寿命。[3]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:

[1]

+ 展开
  • Cell lines: MC 11060细胞
  • Concentrations: ~500 nM
  • Incubation Time: 48小时
  • Method:

    细胞按每孔500个接种在白色, 384孔微孔板,孔中含总体为50 μL的培养基。797, TT和TE10细胞生长在含1% Penicillin/Streptomycin 和 10% FBS的DMEM培养基上。Per403细胞生长在含1 % Penicillin/Streptomycin和20% FBS的DMEM 培养基上。病患衍生的NMC 11060细胞生长在含10% FBS 和1% Penicillin/Streptomycin的RPMI培养基上。通过自动化针转移机将(+)-JQ1置于微量检测板上。使细胞裂解,通过增殖试验测评孔中的总ATP含量。根据剂量,重复测量分析,通过逻辑回归(GraphPad Prism)计算IC50。


    (Only for Reference)
动物实验:

[1]

+ 展开
  • Animal Models: 携带NMC 797移植瘤的小鼠
  • Formulation: 5% DMSO溶于5% 葡萄糖
  • Dosages: 50 mg/kg
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 91 mg/mL warmed (199.12 mM)
Ethanol 91 mg/mL (199.12 mM)
Water Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 456.99
化学式

C23H25ClN4O2S

CAS号 1268524-70-4
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    How can I reconstitute the compound for in vivo injection?

  • 回答:

    JQ1 does not dissolve in water/PBS. The vehicle we recommend is 2% DMSO+30% PEG 300+5% Tween 80+ddH2O. The compound can be dissolved in the vehicle at 5mg/ml and you can use it for IV injection.

Epigenetic Reader Domain Signaling Pathway Map

Epigenetic Reader Domain Inhibitors with Unique Features

Tags: 购买(+)-JQ1 | (+)-JQ1供应商 | 采购(+)-JQ1 | (+)-JQ1价格 | (+)-JQ1生产 | 订购(+)-JQ1 | (+)-JQ1代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID